Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells

Jones, T. Alwyn; Ogunkolade, Babatunji W; Szary, Jarosław; Aarum, Johan; Mumin, Muhammad A.; Patel, Shyam A.; Pieri, Christopher A.; Sheer, Denise

doi:10.1371/journal.pone.0022399

Cited by 23 publications

(30 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BORIS expression has also been examined in the normal cervix and the HeLa cervical adenocarcinoma cell line (Renaud et al, 2011;Jones et al, 2011) but not in LSIL, HSIL, or ICC. In our study, expression of BORIS mRNA was observed in 12.7% of the samples analyzed, with a higher proportion of positive samples in the ICC group than in the LSIL and HSIL groups (P < 0.0005).…”

Section: Discussionmentioning

confidence: 99%

BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer

Velázquez-Hernández¹,

Reyes-Romero²,

Barragán-Hernández³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We investigated the expression of Brother of Regulator of Imprinted Sites (BORIS) and CCCTC-binding factor (CTCF) in squamous intraepithelial lesions and cervical cancer. To analyze BORIS and CTCF expression, an endocervical cytobrush sample was taken for total RNA isolation. CTCF and BORIS mRNA was quantified from total RNA using quantitative reverse transcription-polymerase chain reaction. A total of 71 samples were collected and classified according to the Bethesda Classification of squamous intraepithelial lesions. BORIS 6095 BORIS and CTCF expression in cervical dysplasia and cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 6094-6100 (2015) expression was observed in 9 (12.7%) samples; of these, 5.3, 5.9, 14.8, and 37.5% in the groups that were cytology negative for intraepithelial lesion or malignancy, low-grade squamous intraepithelial lesions (LSIL), highgrade squamous intraepithelial lesions (HSIL), and invasive cervical carcinoma, respectively. The expression level of BORIS was significantly higher in the group with invasive cervical carcinoma as compared with the groups negative for intraepithelial lesion or malignancy, LSIL, and HSIL (P < 0.0005). CTCF mRNA was expressed in all samples. CTCF expression was significantly higher in carcinoma groups compared with LSIL, HSIL, and negative for intraepithelial lesion or malignancy groups. We found that BORIS and CTCF expressions in the LSIL and invasive cervical carcinoma groups were higher than expression in cytological normal samples. Additional studies should be conducted to examine the function of transcription factors during different stages of the transformation of cervical cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer

Velázquez-Hernández¹,

Reyes-Romero²,

Barragán-Hernández³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Several reports indicated that the expression of BORIS is not dependent on the cancerous or non-cancerous nature of cells and tissue. For example, although BORIS has been classified as a CT antigen, but new findings in melanoma, ovarian, prostate, breast, head and neck squamous cell carcinomas, and bladder carcinomas [12,[15][16][17]46] have shown that BORIS expression may not directly correlate with tumorigenicity. These studies reported that Boris expression in primary melanomas (27%) is not as frequent as originally estimated for melanoma cell lines (90%) [17], and when measured quantitatively, levels in tumors were not statistically different from those in normal prostate, bladder, and ovarian tissues [15,16].…”

Section: Boris Expression In Cancer and Non-cancer Mouse Cellsmentioning

confidence: 99%

“…On the contrary, the expression of BORIS cannot be detected in some cancer cell lines or tumors [10,12,[15][16][17]45,46], and has also been detected in several mouse and human somatic tissues and non-cancerous cell lines [17,46,47]. This may point to the widespread expression of BORIS which is not restricted to cancerous cell lines.…”

Section: Introductionmentioning

confidence: 99%

Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states

Soltanian

Dehghani

Matin

et al. 2014

ABBS

View full text Add to dashboard Cite

BORIS/CTCFL is an 11 zinc finger protein, which is the paralog of CTCF, a ubiquitously expressed protein with diverse roles in gene expression and chromatin organization. Several studies have shown that the expression of BORIS is restricted to normal adult testis, pluripotent cells, and diverse cancer cell lines. Thus, it is known as a cancer-testis (CT) gene that has been hypothesized to exhibit oncogenic properties and to be involved in cancer cell proliferation. On the contrary, other reports have shown that its expression is more widespread and can be detected in differentiated and normal somatic cells; hence, it might have roles in general cellular functions. The present study was aimed to analyze the expression of BORIS in different cell states of pluripotent, differentiated, cancerous and non-cancerous. We found that the two cell states of pluripotency and differentiation are not accompanied with significant variations of BORIS expression. Furthermore, Boris transcripts were detected at approximately the same level in cancer and non-cancer cell lines. These findings suggest that, in contrast to some previous reports, the expression of mouse BORIS is not limited to only cancerous cells or pluripotent cell states.

show abstract

“…Its expression has been detected in various cancers and cancer cell lines (D'Arcy et al, 2008;Hoffmann et al, 2006;Hong et al, 2005;Jones et al, 2011;Kholmanskikh et al, 2008;Looijenga et al, 2006;Renaud et al, 2007;Risinger et al, 2007;Smith et al, 2009;Ulaner et al, 2003a;Woloszynska-Read et al, 2007).…”

Section: New Player On the Scene -Borismentioning

confidence: 99%